CELH
Celsius Holdings, Inc.
CELH has the edge over JBS overall, supported by stronger fundamentals and stronger valuation.
JBS
JBS N.V.
JBS has slightly lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
JBS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Under pressure | |
| Strong |
JBS's profitability and balance sheet are currently healthy, but its revenue and cash flow are under pressure.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
JBS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $9.18 | -23% |
| Fair | 11x | $11.89 | -0.1% |
| Current | 11x | $11.90 | — |
| Expensive | 12x | $13.57 | +14% |
Historical ranges are pointers, not guarantees.
JBS has the edge over CELH in the historical PE scenario, which offers more potential upside but is not a forecast.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over JBS on the outlook, with more favorable earnings and revenue expectations.
JBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect JBS's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
JBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $1.11 | +12% |
| Q1 2026 | $1.37 | +56% |
| Q4 2025 | $1.42 | +82% |
| Q3 2025 | $1.21 | +105% |
| Q2 2025 | $0.99 | +209% |
| Q1 2025 | $0.88 | +450% |
| Q4 2024 | $0.78 | +$0.86 |
| Q3 2024 | $0.59 | +490% |
JBS has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over JBS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over JBS on profitability, with a higher operating margin.
JBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.3B | -80% |
| Q1 2026 | $20B | -2.3% |
| Q4 2025 | $22.6B | +8.2% |
| Q3 2025 | $21.6B | +9.1% |
| Q2 2025 | $21.3B | +18% |
| Q1 2025 | $20.4B | +28% |
| Q4 2024 | $20.9B | +21% |
| Q3 2024 | $19.8B | +21% |
JBS's revenue is shrinking: $4.3B last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 2.5% | -2.8 points |
| Q1 2026 | 2.2% | -2.3 points |
| Q4 2025 | 4.1% | -0.7 points |
| Q3 2025 | 5.4% | -2.4 points |
| Q2 2025 | 5.3% | -0.6 points |
| Q1 2025 | 4.5% | +0.5 points |
| Q4 2024 | 4.8% | +3 points |
| Q3 2024 | 7.8% | +4.9 points |
JBS's operating margin was 2.5% last quarter, down 2.8 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH has the edge over JBS on cash flow, with more consistent year-over-year improvement.
JBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $42.9M | -39% |
| Q1 2026 | -$1.3B | -$394.8M |
| Q4 2025 | $1.1B | +1.6% |
| Q3 2025 | $518.4M | -52% |
| Q2 2025 | $69.8M | -94% |
| Q1 2025 | -$857.2M | -$396.5M |
| Q4 2024 | $1.1B | +21% |
| Q3 2024 | $1.1B | +76% |
JBS still generates free cash flow, though less than at its 2020 peak: $383M over the past year.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
JBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.3% | -56.8M shares |
| 1 year | -54% | -1.2B shares |
| 3 years | -54% | -1.2B shares |
| 5 years | -59% | -1.5B shares |
| Available history | -62% | -1.6B shares |
JBS has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $236.4M |
| Q3 2025 | $1.8B |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
JBS spent $2.1B buying back its own shares over the past year, after none the year before.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over JBS on leverage, with a lower net debt burden relative to earnings.
JBS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.7x | Moderate |
| Q3 2024 | 2.9x | Moderate |
JBS's net debt is less than a year of its operating earnings (EBITDA), down from 2.4 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
JBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.6 | Neutral |
| Stochastic | 45.0 | Neutral |
JBS's weekly RSI is 41 (neutral) and its Stochastic is 45 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
JBS PE vs Consumer Defensive Sector
| Metric | JBS | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 19x | 45% below |
| PE % | 51 | 34 | 17 pts above |
JBS has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has stronger trend alignment. CELH is above 2 of 5 weekly averages versus JBS above 0 of 3.
JBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 3.4% below |
| 20 week MA | $12.7 | 6.2% below |
| 50 week MA | $14.1 | 15% below |
JBS is in a downtrend: it's below all three of its weekly moving averages, and 15% below its 50-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
JBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $13.9 | $14.6 | +5% |
| 2026 YTD | $14.6 | $11.9 | -18% |
JBS has the edge over CELH on returns for 2026, with the stronger performance.